Leading the way to safer medication
 Crosscheck  Recommender

Bosutinib

Description

Bosutinib belongs to a pharmacological class of medicinal products known as kinase inhibitors. Bosutinib inhibits the abnormal BCR-ABL kinase that promotes CML. Modeling studies indicate that bosutinib binds the kinase domain of BCR-ABL. Bosutinib is also an inhibitor of Src family kinases including Src, Lyn and Hck. Bosutinib minimally inhibits platelet-derived growth factor (PDGF) receptor and c-Kit. In in vitro studies, bosutinib inhibits proliferation and survival of established CML cell lines, Ph+ ALL cell lines, and patient-derived primary primitive CML cells.

ATC Classification

Code
Title
Category
L01EA04
Bosutinib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EA BCR-ABL tyrosine kinase inhibitors

Trade names

Trade name
Countries

Austria Canada Cyprus France Netherlands

Product Monographs

Monograph
Type
Country
BOSULIF Film-coated tablet
MPI, EU: SmPC